Table 2 Patients’ clinicopathological features of IR and TM in T>3cm
Characteristic feature | IR (N=61) | TM (N=61) | P |
|---|---|---|---|
n (%) | n (%) | ||
Age | Matching variable | ||
 ≤35 | 33 (54.10) | 33 (54.10) |  |
 >35 | 28 (45.90) | 28 (45.90) |  |
pT | Matching variable | ||
 T2(>3cm, ≤5cm) | 46 (75.41) | 46 (75.41) |  |
 T3(>5cm) | 15 (24.59) | 15 (24.59) |  |
pN | Matching variable | ||
 N0 | 16 (26.23) | 16 (26.23) |  |
 N1-3 | 45 (73.77) | 45 (73.77) |  |
Stage | 0.706 | ||
 II | 21 (34.43) | 23 (37.70) |  |
 III | 40 (65.57) | 38 (62.30) |  |
HG | 0.820 | ||
 I | 6 (9.84) | 7 (11.48) |  |
 II | 47 (77.05) | 44 (72.13) |  |
 III | 8 (13.11) | 10 (16.39) |  |
ER | 0.691 | ||
 ER (+) | 44 (72.13) | 42 (68.85) |  |
 ER (-) | 17 (27.87) | 19 (31.15) |  |
PR | 0.455 | ||
 PR (+) | 36 (59.02) | 40 (65.57) |  |
 PR (-) | 25 (48.98) | 21 (34.43) |  |
Her2 | 0.700 | ||
 Her2 (+) | 21 (34.43) | 19 (31.15) |  |
 Her2 (-) | 40 (65.57) | 42 (69.85) |  |
Ki67 | 0.817 | ||
 Ki67 (≤ 14%) | 11 (16.39) | 12 (19.67) |  |
 Ki67 (>14%) | 50 (83.61) | 49 (80.33) |  |
Subtype | 0.986 | ||
 Luminal A | 10 (16.39) | 9 (36.77) |  |
 Luminal B | 24 (39.34) | 25 (40.98) |  |
 Her2+ | 13 (21.31) | 14 (22.95) |  |
 TN | 14 (22.95) | 13 (21.31) |  |
Chemotherapy | 0.638 | ||
 Yes | 49 (65.81) | 51 (83.61) |  |
 No | 12 (34.19) | 10 (16.31) |  |
Hormone therapy | 0.691 | ||
 Yes | 42 (68.85) | 44 (72.13) |  |
 No | 19 (31.15) | 17 (27.87) |  |
Radiotherapy | 0.277 | ||
 Yes | 29 (47.54) | 35 (57.38) |  |
 No | 32 (52.46) | 26 (42.62) |  |
Anti-Her2 therapy | 0.894 | ||
 Yes | 18 (85.71) | 16 (84.21) |  |
 No | 3 (14.29) | 3 (15.79) |  |
Local recurrence | 0.126 | ||
 Yes | 12 (19.67) | 6 (9.83) |  |
 No | 49 (80.33) | 55 (90.16) |  |
Distant metastasis | 0.408 | ||
 Yes | 9 (14.75) | 6 (9.83) |  |
 No | 52 (85.25) | 55 (90.17) |  |